Hi Rhonda,I wish the testing were available commercially but it hasn't been validated yet.We are working hard to do this! At the moment, while our paper makes animportant observation, we are not yet aware how Cyclin D1 influences response totherapy. In some cases factors that make the prognosis worse don't influence thebenefit of therapy, in other cases they do. In other words, the therapy mayremove the negative prognosis. We hope to learn more about this very soon!I have just joined the Yale Cancer Center as Director of the Breast CancerProgram. If I can be of any help, please feel free to contact me.
lyndsay.harris@yale.edu.bestLyndsay N. Harris, MDAssociate Professor of MedicineDirector, Breast Disease UnitYale School of Medicine118 Fitkin BldgNew Haven, CTPhone: 203-737-1600Fax: 203-785-3788________________________________From: rhonda r hoffman [
mailto:hoffman_brown@msn.com]Sent: Mon 1/23/2006 12:42 PMTo: Harris, Lyndsay N.,M.D.Subject: Cyclin dDr. Harris, I have a followup question to my earlier email
oes anyone know how we get tested for the cyclin d?Sincerely, Rhonda Hoffman